A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors

Inclusion Criteria: * Histology: Metastatic castration-resistant prostate cancer (mCRPC) with histologic confirmation of adenocarcinoma. Adenocarcinoma with small-cell or neuroendocrine features is allowed * Measurable or evaluable disease * Prior treatment with at least 1 prior novel androgen receptor (AR)-targeted therapy or chemotherapy * If the participant is receiving treatment with gonadotropin-releasing hormone agonists or antagonist analogs (GnRH), this therapy must have been initiated prior to first dose of study drug and must be continued throughout the study * Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1 * Adequate organs functions Exclusion Criteria: * Known brain metastases * Concurrent use of any other anticancer treatment or investigational agent for the treatment of advanced disease * Toxicities related to prior anticancer treatments have not returned to Grade less than or equal to (\<=) 1 or baseline, except for alopecia and vitiligo * Solid organ or bone marrow transplantation * Known allergies, hypersensitivity, or intolerance to JNJ-70218902 or its excipients * Certain comorbidities